Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|5.30536.0001||Glass bottle||25 mg||
|Overview||A nitro-benzoxadiazole (NBD) compound that directly binds to the dimerization domain of sEGF receptor to generate stable dimers and allosterically activates the receptor. Exhibits similar phosphorylation profile as the cognate EGF-ligand. Enhances the phosphorylation of Tyr1068 and Tyr1173 in MDA-MB-468 cells in a time- and dose-dependent manner (EC50 = 52 µM with respect to Tyr1068). These phosphorylation events can be blocked by pre-incubating cells with AG1478 (Cat. No. 658852; 10 µM) or PD153035 (Cat. No. 234490; 2 µM) that selectively block the ATP-binding pocket of EGFR. Tyr1068 phosphorylation of the receptor can also be completely blocked in EGF treated MDA-MB-468 cells exposed to anti-EGFR neutralizing antibody.
Please note that the molecular weight for this compound is batch-specific due to variable water content.
|Synonyms||4-Nitro-7-((1-oxidopyridin-2-yl)sulfanyl)-2,1,3-benzoxadiazole, 4-Nitro-7-(1-oxy-pyridin-2-ylsulfanyl)-benzo[1,2,5]oxadiazole, 2-(7-Nitrobenzo[c][1,2,5]oxadiazol-4-ylthio)pyridine-1-oxide, NSC-228155|
|References||Sakanyan, V., et al. 2014. Sci. Rep. 4, 3977.|
|Form||Burnt orange powder|
|Primary Target||EGF receptor|
|Purity||≥97% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
|Sakanyan, V., et al. 2014. Sci. Rep. 4, 3977.|
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.